BioSpace News Archive

Medline, a market-leading manufacturer and supplier of medical supplies and solutions, announced that it achieved the Diamond-level HIRC Resiliency Badge for distribution, a recognition of the company’s relentless commitment to resiliency within the healthcare supply chain.

Neurolief, a leading developer of innovative brain neuromodulation technologies, announces the groundbreaking topline results from its pivotal clinical trial evaluating the efficacy and safety of its revolutionary brain neuromodulation therapy for patients suffering from Treatment Resistant Depression (TRD).

Strenge Spine Center, a pioneering provider of advanced spine care, is proud to announce the launch of its state-of-the-art technologies and innovative treatment options, including the EOSedge system.

Camurus (NASDAQ STO: CAMX) today announced the publication in JAMA Network Open of a new post hoc analysis from a 24-week randomized, double-blind, Phase 3 study1 comparing weekly and monthly subcutaneous (SC) buprenorphine injections (Buvidal®/Brixadi®) to daily sublingual buprenorphine/naloxone (SL-BPN/NX).

NeuroBo Pharmaceuticals, Inc. announced the closing of its previously announced sale in a private placement of 4,325,701 shares of its common stock, at a purchase price of $3.93 per share.

Hyundai Bioscience (CEO Oh Sang-gi), which is preparing for a dengue fever basket clinical trial in Brazil, announced on the 24th that it has successfully developed a ‘multi-treatment drug for mosquito-borne viral infections, including dengue fever,’ using niclosamide as the main ingredient.

Charles River Laboratories International, Inc. today announced a lentiviral vector contract development and manufacturing organization (CDMO) agreement.

Harmony Biosciences today announced that the U.S. Food and Drug Administration denied the Citizen Petition filed by a short seller claiming that WAKIX is not safe and effective for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy.

CDR-Life Inc. today announced an expansion of its pipeline of novel T cell engagers (TCE) with the addition of CDR813 and CDR505.